$761.17
-16.08(-2.07%)
Mkt Cap $79.1B
$483.07
$812.27
52-Week Range
At A Glance
1
Regeneron Pharmaceuticals, Inc.
2
Revenue is primarily driven by Product (20.4%) and Collaboration Revenue (18.3%).
3
Most recently: . The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities E (2026-01-30).
$79.1B
Market Cap
$14.5B
Revenue
$4.5B
Net Income
Employees15,158
Fundamentals
How The Business Makes Money
Revenue by Segment
Product20.4%($21.0B)
Collaboration Revenue18.3%($18.9B)
Share Of Profit Losses15.9%($16.4B)
ELYEAHD And EYLEA15.8%($16.2B)
Eylea Net Product Sales12.9%($13.2B)
LIBTAYO Net Product Sales6.9%($7.1B)
ELYEAHD2.9%($3.0B)
Reimbursement For Manufacturing Of Commercial Supplies2.1%($2.2B)
Reimbursement Of Commercialization Related Expenses1.9%($1.9B)
Product And Service Other1.7%($1.8B)
Praluent Net Product Sales0.7%($687M)
Evkeeza0.4%($365M)
Inmazeb0.2%($184M)
Sales Based Milestone Earned0%($50M)
Other Products0%($10M)
Revenue by Geography
US86.4%($36.0B)
Non Us13.6%($5.7B)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0000872589
ISINUS75886F1075
CUSIP75886F107
Phone914 847 7000
Address777 Old Saw Mill River Road, Tarrytown, NY, 10591-6707, US
SEC EDGAR